{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:32:28Z","timestamp":1790191948034,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The science, Technology, & Innovation Funding Authority (STDF), in cooperation with the Egyptian Knowledge Bank (EKB), provides open-access funding."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06701-7","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T02:17:50Z","timestamp":1763173070000},"page":"6131-6145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4313-1513","authenticated-orcid":false,"given":"Eman Ayman","family":"Nada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5190-2763","authenticated-orcid":false,"given":"Mohamed Abdelhalim","family":"Elfagieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6879-1652","authenticated-orcid":false,"given":"Fares","family":"Abdelsalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8312-3959","authenticated-orcid":false,"given":"Asmaa Ahmed","family":"Elrashedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4677-9980","authenticated-orcid":false,"given":"Fatima A.","family":"Idres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0704-6585","authenticated-orcid":false,"given":"Abdelrahman","family":"shata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M.","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9122-7280","authenticated-orcid":false,"given":"Hasan Mohammad Masoum","family":"Hamoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6901-6946","authenticated-orcid":false,"given":"Radwa Mohamed","family":"Awadalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2173-9984","authenticated-orcid":false,"given":"Israa Ahmed","family":"Qutob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belal Mohamed","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"key":"6701_CR1","doi-asserted-by":"crossref","unstructured":"Spivak JL (2018) Polycythemia Vera. Curr Treat Options Oncol 19(2)","DOI":"10.1007\/s11864-018-0529-x"},{"issue":"6","key":"6701_CR2","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00277-015-2357-4","volume":"94","author":"M Griesshammer","year":"2015","unstructured":"Griesshammer M, Gisslinger H, Mesa R (2015) Current and future treatment options for polycythemia Vera. Ann Hematol 94(6):901\u2013910","journal-title":"Ann Hematol"},{"issue":"9","key":"6701_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc2210","volume":"7","author":"RL Levine","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7(9):673\u2013683","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"6701_CR4","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/leu.2011.92","volume":"25","author":"A Tefferi","year":"2011","unstructured":"Tefferi A (2011) Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up. Leukemia 25(7):1059\u20131063","journal-title":"Leukemia"},{"issue":"1","key":"6701_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","volume":"41","author":"HC Hasselbalch","year":"2019","unstructured":"Hasselbalch HC, Holmstr\u00f6m MO (2019) Perspectives on interferon-alpha in the treatment of polycythemia Vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol 41(1):5\u201319","journal-title":"Semin Immunopathol"},{"issue":"6","key":"6701_CR6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R (2017) Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 129(6):667\u2013679","journal-title":"Blood"},{"issue":"33","key":"6701_CR7","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1200\/JCO.2015.61.6474","volume":"33","author":"BL Stein","year":"2015","unstructured":"Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK et al (2015) Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F. J Clin Oncol 33(33):3953\u20133960","journal-title":"J Clin Oncol"},{"issue":"9","key":"6701_CR8","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.mayocp.2015.05.014","volume":"90","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Barbui T (2015) Essential thrombocythemia and polycythemia vera: focus on clinical practice. Mayo Clin Proc 90(9):1283\u20131293","journal-title":"Mayo Clin Proc"},{"issue":"20","key":"6701_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"2","key":"6701_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P et al (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8(2):15","journal-title":"Blood Cancer J"},{"key":"6701_CR11","doi-asserted-by":"publisher","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM et al (2022) International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u201328.\u00a0https:\/\/doi.org\/10.1182\/blood.2022015850","DOI":"10.1182\/blood.2022015850"},{"key":"6701_CR12","doi-asserted-by":"publisher","unstructured":"Xiao W, Nardi V, Stein E, Hasserjian RP (2024) A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC. J Hematol Oncol 17(1):56. https:\/\/doi.org\/10.1186\/s13045-024-01571-4","DOI":"10.1186\/s13045-024-01571-4"},{"key":"6701_CR13","doi-asserted-by":"publisher","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H et al (2022) Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol 9(4):e301\u201311. https:\/\/doi.org\/10.1016\/S2352-3026(22)00046-1","DOI":"10.1016\/S2352-3026(22)00046-1"},{"key":"6701_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","volume":"202","author":"S Pestka","year":"2004","unstructured":"Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8\u201332","journal-title":"Immunol Rev"},{"issue":"32","key":"6701_CR15","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","volume":"27","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S et al (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia Vera. J Clin Oncol Off J Am Soc Clin Oncol 27(32):5418\u20135424","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"6701_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/cncr.11486","volume":"98","author":"AI Radin","year":"2003","unstructured":"Radin AI, Kim HT, Grant BW, Bennett JM, Kirkwood JM, Stewart JA et al (2003) Phase II study of \u03b12 interferon in the treatment of the chronic myeloproliferative disorders (E5487): A trial of the Eastern cooperative oncology group. Cancer 98(1):100\u2013109","journal-title":"Cancer"},{"key":"6701_CR17","doi-asserted-by":"crossref","unstructured":"How J, Hobbs G (2020) Use of interferon Alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature. Cancers (Basel) 12(7)","DOI":"10.3390\/cancers12071954"},{"key":"6701_CR18","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"6701_CR19","doi-asserted-by":"crossref","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Carobbio A, Ghirardi A, Carioli G et al (2023) Ropeginterferon versus standard therapy for Low-Risk patients with polycythemia Vera. NEJM Evid 2(6)","DOI":"10.1056\/EVIDoa2200335"},{"issue":"3","key":"6701_CR20","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M et al (2020) Ropeginterferon alfa-2b versus standard therapy for polycythaemia Vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 7(3):e196-208","journal-title":"Lancet Haematol"},{"issue":"4","key":"6701_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ajh.23928","volume":"90","author":"NCC Them","year":"2015","unstructured":"Them NCC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D et al (2015) Molecular responses and chromosomal aberrations in patients with polycythemia Vera treated with peg-proline-interferon alpha-2b. Am J Hematol 90(4):288\u2013294","journal-title":"Am J Hematol"},{"issue":"2","key":"6701_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12185-022-03341-9","volume":"116","author":"Y Edahiro","year":"2022","unstructured":"Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T et al (2022) Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol 116(2):215\u2013227","journal-title":"Int J Hematol"},{"issue":"1\u20132","key":"6701_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14740\/jh1245","volume":"13","author":"SS Suo","year":"2024","unstructured":"Suo SS, Fu RF, Qin A, Shao ZH, Bai J, Chen SN et al (2024) Effective management of polycythemia Vera with ropeginterferon Alfa-2b treatment. J Hematol 13(1\u20132):12\u201322","journal-title":"J Hematol"},{"issue":"6","key":"6701_CR24","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/bcp.16043","volume":"90","author":"A Qin","year":"2024","unstructured":"Qin A, Wu D, Li Y, Zhang J, Wang W, Shen W et al (2024) Exposure\u2013efficacy and exposure\u2013safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia Vera. Br J Clin Pharmacol 90(6):1493\u20131502","journal-title":"Br J Clin Pharmacol"},{"issue":"15","key":"6701_CR25","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA et al (2015) Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia Vera. Blood 126(15):1762\u20131769","journal-title":"Blood"},{"issue":"3","key":"6701_CR26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/ijc.35411","volume":"157","author":"SY Yoon","year":"2025","unstructured":"Yoon SY, Yoon S, Yang D, Lee G, Sohn SK, Shin H et al (2025) Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48\u2010week results from a prospective study. Int J Cancer 157(3):526\u2013533","journal-title":"Int J Cancer"},{"issue":"5","key":"6701_CR27","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1111\/bcp.15176","volume":"88","author":"Y Huang","year":"2022","unstructured":"Huang Y, Qin A, Fang J, Wang T, Tsai C, Lin K et al (2022) Novel long-acting ropeginterferon alfa\u20102b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial. Br J Clin Pharmacol 88(5):2396\u20132407","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"6701_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40261-021-01026-5","volume":"41","author":"N Miyachi","year":"2021","unstructured":"Miyachi N, Zagrijtschuk O, Kang L, Yonezu K, Qin A (2021) Pharmacokinetics and pharmacodynamics of ropeginterferon Alfa-2b in healthy Japanese and Caucasian subjects after single subcutaneous administration. Clin Drug Investig 41(4):391\u2013404","journal-title":"Clin Drug Investig"},{"key":"6701_CR29","doi-asserted-by":"crossref","unstructured":"Chen C, Chuang W, Qin A, Zhang W, Zhu L, Zhang G et al (2022) A phase 3 clinical trial validating the potency and safety of an innovative, extra-long\u2010acting\u2009interferon in chronic hepatitis C JGH Open 6(11):782\u2013791","DOI":"10.1002\/jgh3.12825"},{"issue":"5","key":"6701_CR30","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"JJ Kiladjian","year":"2022","unstructured":"Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M et al (2022) Long-term outcomes of polycythemia Vera patients treated with ropeginterferon Alfa-2b. Leukemia 36(5):1408\u20131411","journal-title":"Leukemia"},{"issue":"S2","key":"6701_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00292-016-0240-2","volume":"37","author":"A Mullally","year":"2016","unstructured":"Mullally A (2016) Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms. Pathologe 37(S2):175\u2013179","journal-title":"Pathologe"},{"key":"6701_CR32","doi-asserted-by":"crossref","unstructured":"Guglielmelli P, Loscocco GG, Mannarelli C, Rossi E, Mannelli F, Ramundo F et al (2021) JAK2V617F variant allele frequency\u2009>\u200950% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J 11(12). https:\/\/pubmed.ncbi.nlm.nih.gov\/34897288\/","DOI":"10.1038\/s41408-021-00581-6"},{"key":"6701_CR33","doi-asserted-by":"crossref","unstructured":"Moliterno AR, Kaizer H, Reeves BN (2023) JAK2 V617F allele burden in polycythemia vera: burden of proof. Blood 141(16):1934\u201342.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/36745865\/","DOI":"10.1182\/blood.2022017697"},{"issue":"2","key":"6701_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12185-014-1721-9","volume":"101","author":"S Shirane","year":"2015","unstructured":"Shirane S, Araki M, Morishita S, Edahiro Y, Sunami Y, Hironaka Y et al (2015) Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia Vera and essential thrombocythemia. Int J Hematol 101(2):148\u2013153","journal-title":"Int J Hematol"},{"issue":"19","key":"6701_CR35","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2021012743","volume":"139","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A et al (2022) A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia Vera and essential thrombocythemia. Blood 139(19):2931\u20132941","journal-title":"Blood"},{"issue":"12","key":"6701_CR36","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/ajh.24592","volume":"91","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Primary myelofibrosis (2016) 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 91(12):1262\u20131271","journal-title":"Am J Hematol"},{"key":"6701_CR37","doi-asserted-by":"publisher","unstructured":"Parasuraman S, DiBonaventura M, Reith K, Naim A, Concialdi K, Sarlis NJ (2016) Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. Exp Hematol Oncol 5(1):1\u201310. https:\/\/ehoonline.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s40164-016-0031-8","DOI":"10.1186\/s40164-016-0031-8"},{"issue":"20","key":"6701_CR38","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1182\/bloodadvances.2018021436","volume":"2","author":"NA Podoltsev","year":"2018","unstructured":"Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ et al (2018) The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia Vera. Blood Adv 2(20):2681\u20132690","journal-title":"Blood Adv"},{"issue":"5","key":"6701_CR39","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/bjh.13886","volume":"172","author":"A Alvarez-Larr\u00e1n","year":"2016","unstructured":"Alvarez-Larr\u00e1n A, Kerguelen A, Hern\u00e1ndez\u2010Boluda JC, P\u00e9rez\u2010Encinas M, Ferrer\u2010Mar\u00edn F, B\u00e1rez A et al (2016) Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia Vera. Br J Haematol 172(5):786\u2013793","journal-title":"Br J Haematol"},{"issue":"22","key":"6701_CR40","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1182\/bloodadvances.2019000655","volume":"3","author":"J Hong","year":"2019","unstructured":"Hong J, Lee JH, Byun JM, Lee JY, Koh Y, Shin DY et al (2019) Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms. Blood Adv 3(22):3700\u20133708","journal-title":"Blood Adv"},{"issue":"10","key":"6701_CR41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-018-0133-0","volume":"8","author":"E Verger","year":"2018","unstructured":"Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z et al (2018) Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia Vera cells in vitro and in vivo. Blood Cancer J 8(10):94","journal-title":"Blood Cancer J"},{"issue":"11","key":"6701_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/genes7110099","volume":"7","author":"A Singh","year":"2016","unstructured":"Singh A, Xu YJ (2016) The cell killing mechanisms of hydroxyurea. Genes (Basel) 7(11):99","journal-title":"Genes (Basel)"},{"issue":"5","key":"6701_CR43","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.3324\/haematol.2015.139691","volume":"101","author":"Y Beauverd","year":"2016","unstructured":"Beauverd Y, Radia D, Cargo C, Knapper S, Drummond M, Pillai A et al (2016) Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Haematologica 101(5):e182\u2013e184","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06701-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06701-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06701-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:08Z","timestamp":1767485708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06701-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6701"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06701-7","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}